Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Instalación única de bioprototipado para investigación y desarrollo de productos de alto valor mediante el uso de un sistema de expresión basado en plantas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20170521001
Publicado:
26/05/2017
Caducidad:
26/05/2018
Resumen:
Una empresa británica de biociencias ha creado una nueva instalación vanguardista de bioprototipado con una tecnología basada en plantas que permite la expresión y producción de cantidades escalables de productos bioactivos. Esta tecnología ofrece un método rápido y escalable y la oportunidad de reducir el tiempo de desarrollo de nuevos metabolitos farmacéuticos, agroaquímicos, biológicos y complejos. Sus aplicaciones potenciales incluyen la producción de proteínas complejas y antígenos, prototipado rápido y producción en respuesta a circunstancias externas, e ingeniería metabólica. La empresa ofrece oportunidades de cooperación técnica e investigación.

Details

Tittle:
Unique bio-prototyping facility for research and development of high value products using a plant based expression system.
Summary:
A UK based bioscience company has established a new state of the art bio-prototyping facility based on plant based technology that allows the expression and production of scalable quantities of bio-active products. The technology provides a quick and scalable method and the opportunity to shorten the development time for new pharmaceutical, agrichemicals, biologicals and complex metabolites. It offers opportunities for research cooperation and technical cooperation agreements.
Description:
One of the key factors delaying the introduction of new vaccines and other biomedical products is the time taken to express and produce scalable quantities of the complex proteins, metabolites and other complex natural products required for such development.

A UK SME has been established to exploit proprietary technology arising from a world-renowned plant science research institute that uses plant systems to express and produce scalable quantities of such chemicals in far shorter time scales than traditional methods. This bio-prototyping technology has the potential to reduce the development time for new vaccines from the typical 14 months to 4 months thus enabling, for example, far more effective strategic responses to new disease epidemic threats world-wide.

Potential applications of the technology include:
· Production of complex proteins, such as antibodies or enzymes for research applications.
· Production of antigens including virus-like particles for vaccine development or nanotechnology.
· Rapid prototyping and surge production in response to external circumstances.
· Metabolic pathway engineering to generate complex biochemicals that are difficult or impossible to synthesise chemically or are only found in rare species or trace amounts in nature.

The company has established a brand new, state of the art pilot plant facility which it now offers to prospective partners as a resource to be used in the research and development of new biomedical products. Specifically it will consider the following types of collaborative agreement:
· Research cooperation: -to use the facility as a tool for joint exploratory research around target products that could exploit the Hypertrans technology.
· Technical cooperation: -to work with a partner in the development of a new biomedical product using the plant based expression system.
Advantages and Innovations:
· Rapid expression and production of scalable quantities of complex biochemicals can potentially reduce development time for strategically important products by over 70%.
· Reduced development times so can significantly reduce development costs for new biomedical products.
· Availability of this unique technology is supported by world-renowned and respected scientific expertise and knowledge.
· Proven industrial scale capability of technology to produce influenza vaccines
Stage of Development:
Available for demonstration
IPs:
Secret Know-how,Exclusive Rights
CommeR Statunts Regarding IPR Status:
The core technology is based on proprietary knowledge for which the company has been granted exclusive rights by the research institution. Ownership of any new intellectual property arising as a result of the envisaged collaboration will be governed by the specific cooperation agreements.

Partner sought

Type and Role of Partner Sought:
Research institutes, university research teams and industrial partners. The partner may have already identified a synthetic route using specific complex chemical species for which it needs scalable quantities to further the development. Alternatively it may be wishing to collaborate with a partner in a joint research and development project, identifying new applications for particular biochemical species and rapidly testing the technical and commercial viability of each with scalable quantities of material.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06002006 Biología sintética
06002004 Ingeniería de proteínas